ライフサイエンスコーパス: humoral

1 otensin system, further exacerbates sympatho-humoral activation during hypertension.

2 re evaluated using a noninvasive NK-cellular humoral activation test.

3 ld-type C57BL/6 mice mount cell-mediated and humoral adaptive immune responses to ZIKV, these respons

4 the liver, but not in tumor tissue, without humoral adverse effects.

5 the liver, but not in tumor tissue, without humoral adverse effects.

6 raft histology in spite of apparently active humoral allo-immune responses.

7 Overlooked for decades, the humoral alloimmune response is increasingly recognized a

8 dies on sensitization and effector phases of humoral alloreactivity as well as efficacy testing of fu

9 -1 does not regulate the primary cellular or humoral alloresponse and is not required for long-term t

10 o peach has been produced and changes in the humoral and basophil responses have been analysed.

11 weekly via in vivo electroporation, and both humoral and CD8 T cell responses were mapped and measure

12 vaccine against Ct should elicit protective humoral and cell-mediated immune (CMI) responses in the

13 n and that KyA infection elicited protective humoral and cell-mediated immune responses.

14 hepatitis C virus (HCV) infection decreases humoral and cell-mediated immunity responses to hepatiti

15 ce via the intranasal route and induced both humoral and cell-mediated immunity.

16 nization with p24-SIgA elicits both a strong humoral and cellular immune response against p24 at the

17 several intracellular pathogens, where both humoral and cellular immune responses are desired.

18 While humoral and cellular immune responses are well described

19 This vaccine stimulated strong humoral and cellular immune responses in mice, suggestin

20 owing infection, WT mice mounted more robust humoral and cellular immune responses than HLA-DR4 mice.

21 effective AIDS vaccine should elicit strong humoral and cellular immune responses while maintaining

22 cine candidates because they can elicit both humoral and cellular immune responses.

23 an acceptable safety profile and stimulated humoral and cellular immune responses.

24 nization of mice results in strong antiviral humoral and cellular immune responses.

25 nza virus hemagglutinin antigen induction of humoral and cellular immunity against viral challenges.

26 V) surface antigen (HBsAg) sometimes develop humoral and cellular immunity to HBV proteins such as co

27 venue to study pTreg, the cross-talk between humoral and cellular immunity, and regulation of the inf

28 in C-PfCSP may benefit parasite escape from humoral and cellular immunity.

29 nogaster group, activates NF-kappaB-mediated humoral and cellular immunity.

30 GAMP represents a potent vaccine adjuvant of humoral and cellular immunity.

31 on; however, it is unknown whether combining humoral and cellular immunization might act synergistica

32 A challenge, and then they were examined for humoral and cellular immunological profiles, airway hype

33 ly immunogenic, as two doses elicited potent humoral and cellular responses in mice that exceed the t

34 A-ZIKV-NS1 vaccine candidate provided robust humoral and cellular responses, and afforded 100% protec

35 n vivo, conferring IL-21 with a role in both humoral and cellular responses.

36 h to learn about the quantity and quality of humoral and cellular vaccine responses in healthy and im

37 Harnessing humoral and innate cellular responses has become one foc

38 designs that aim for effective and balanced humoral and T cell responses.

39 GP+RAP, or GP+RAP/alpha-syn (combined active humoral and Treg) and analyzed using neuropathological a

40 ed through elicitation of protective innate, humoral, and cellular responses.

41 C2 domains, contributes significantly to the humoral anti-fVIII immune response in acquired and conge

42 2e-tFliC MNP boost could better maintain the humoral antibody response than that by the conventional

43 on exposes ZnT8 to the cell surface, but the humoral antigenicity of the surface-displayed ZnT8 remai

44 ty to antibacterial components of the immune humoral arm.

45 Thus, PTX3 may bridge the humoral arms of the innate and adaptive immune systems b

46 Thus, vaccine microparticles could trigger humoral as well as cellular immune response when adminis

47 Utilizing an array of humoral assays, we evaluated the magnitudes, epitope spe

48 parasitic infections, but also arise during humoral autoimmune disease in both mouse models and huma

49 t the Ox40/Ox40L pathway drives cellular and humoral autoimmune responses during lupus nephritis in N

50 novel mechanism through which BAFF promotes humoral autoimmunity via direct, TACI-dependent activati

51 y, aging Stim1Stim2-deficient mice developed humoral autoimmunity with spontaneous autoantibody produ

52 th a potential contribution to BAFF-mediated humoral autoimmunity, TACI(+) transitional B cells from

53 patients with expanded CD21(low) B cells and humoral autoimmunity.

54 first study to demonstrate that LAIV elicits humoral B-cell responses in tonsils of young children.

55 o levels that enable the xenotransplantation humoral barrier to be overcome.

56 proved adjuvants for infectious agents boost humoral but not cellular immunity, and have poorly-under

57 (CMV) infection is highly complex, including humoral, cellular, innate, and adaptive immune responses

58 We hypothesized that cellular and humoral components of innate immunity alter fate and mig

59 provide a general guide to the cellular and humoral contributors to inflammation as well as to the p

60 taining to ZIKV-induced B-cell responses and humoral cross-reactivity and discuss relevant considerat

61 ary oxygenation, and levels of endotoxin and humoral cytokines.

62 e latter is more likely to contribute to the humoral deficiency.

63 Three distinct humoral epitope-containing regions have been defined wit

64 cluded that erythropoiesis is regulated by a humoral factor rather than by a direct oxygen effect on

65 re used to test whether females have a toxic humoral factor; if so, then its strength was compared wi

66 exception of interleukin-1alpha, none of the humoral factors changed in their concentrations after RI

67 ult from the translocation of leukocytes and humoral factors from the vasculature, first across the e

68 ls need to communicate with stromal cells by humoral factors such as VEGF, FGFs, and Wnt in order to

69 echanism, PMVDS robustly stimulated both the humoral (>32 times of IgG1 levels vs alum) and the cell-

70 ATF as a central modulator of peripheral and humoral hallmarks of type-2 immunity and begin to elucid

71 us (EBOV-GP1,2) is the primary target of the humoral host response.

72 neering may make it possible to overcome the humoral immune barrier that prevents xenotransplantation

73 cardiac defects, KS is also characterized by humoral immune deficiency and autoimmune disease, yet no

74 t injury, and effective strategies targeting humoral immune reactivity are needed to improve long-ter

75 e primary objective of noninferiority of the humoral immune response 1 month post-dose 2 was consider

76 ly to enhance the breadth and potency of the humoral immune response against HCV.

77 ew networks that have important functions as humoral immune response and organismal injury/abnormalit

78 oses immense immunological challenges to the humoral immune response because of its ability to shield

79 mulation showed more robust and long-lasting humoral immune response compared to a single bolus injec

80 burden, resistant mice exhibited an elevated humoral immune response compared with susceptible mice.

81 rane fusion and is the primary target of the humoral immune response during infection.

82 insic manner to mount an effective long-term humoral immune response following immunization.

83 pointed to the potential for harnessing the humoral immune response for early cancer detection.

84 Although the humoral immune response generates the primary correlate

85 ecent findings related to B cells and to the humoral immune response in cancer and their translationa

86 in alteration is associated with a decreased humoral immune response in Rictor KO mice.

87 ynthetic DNA adjuvant, eliciting an enhanced humoral immune response in vaccinated mice.

88 rotein antigens are conjugated with DNA, the humoral immune response is blunted and acquires features

89 fect on the induction and progression of the humoral immune response is not fully understood.

90 new avenues to a better understanding of the humoral immune response to CMV and development of more e

91 underlie the best available examples of the humoral immune response to HIV are providing important i

92 In 430 participants, humoral immune response to HZ/su was noninferior in HZ-P

93 This is best exemplified during humoral immune response when an expanding B cell clone a

94 During the humoral immune response, B cells undergo a dramatic chan

95 HIV employs multiple means to evade the humoral immune response, particularly the elicitation of

96 vement, cell-cell signaling and interaction, humoral immune response, protein synthesis, cell death a

97 iated activation of MZ B is known to trigger humoral immune response, the signal cascade directing th

98 virus spread, which is resistant to the host humoral immune response.

99 cell formation, directly linking EG with the humoral immune response.

100 hether and to what extent 9cRA modulates the humoral immune response.

101 ndent on neither cytotoxic T lymphocytes nor humoral immune response.

102 antibody production, signifying an increased humoral immune response.

103 d play important roles in T cell-independent humoral immune responses against blood-borne pathogens.

104 Humoral immune responses against donor antigens are impo

105 ts/cells that are responsible for sustaining humoral immune responses against HIV.

106 MN vaccine induced superior humoral immune responses and conferred protective immuni

107 alled IL-40, that plays an important role in humoral immune responses and may also play a role in B c

108 The BuV-specific humoral immune responses appeared to be strong and long-

109 that the suppressive effects on Ag-specific humoral immune responses are entirely B cell intrinsic.

110 s play an essential role in antigen-specific humoral immune responses by differentially regulating B

111 However, CPS-specific adaptive humoral immune responses can only be achieved by the cov

112 that can induce strong and broad T cell and humoral immune responses correlating with HIV-1 protecti

113 B cells ensure humoral immune responses due to the production of Ag-spe

114 Humoral immune responses have the potential to maintain

115 immunity, but whether and how mTOR modulates humoral immune responses have yet to be fully understood

116 used to analyze the established cellular and humoral immune responses in healthy adults and asthmatic

117 nts in cervical lymph nodes (CLN) to driving humoral immune responses in the infected CNS is poorly d

118 The patterns of humoral immune responses in the natural host are therefo

119 ses, but their control of TFH cell-dependent humoral immune responses is unknown.

120 lls play roles in both normal and pathogenic humoral immune responses regardless of host age.

121 -viral vector boosts to enhance cellular and humoral immune responses remains poorly understood.

122 the PC that could be an important target of humoral immune responses that are involved in protection

123 that a live-attenuated HSV-1 vaccine elicits humoral immune responses that are unparalleled by a glyc

124 onses induced by nasal allergen exposure and humoral immune responses that included IgE-dependent bas

125 e podocyte, and both induce IgG4-predominant humoral immune responses that produce circulating autoan

126 ficantly less likely to develop long-lasting humoral immune responses to DENV, as measured in healthy

127 Most humoral immune responses to influenza virus target the h

128 emulsion (GLA-SE) augments both cellular and humoral immune responses to vaccine Ags.

129 a model Ag, we investigated the evolution of humoral immune responses toward its immunodominant seque

130 post-RABV immunization.IMPORTANCE Extending humoral immune responses using adjuvants is an important

131 Concurrent induction of potent cellular and humoral immune responses was also achieved by combining

132 t clinical symptoms, although DTMUV-specific humoral immune responses were detected.

133 We investigated cellular and humoral immune responses when allogeneic hepatocytes are

134 prehensive approach to systematically survey humoral immune responses, capturing the array of functio

135 V-positive C cases did not elicit long-lived humoral immune responses, despite viremia levels of up t

136 ntal understanding of coordinated aspects of humoral immune responses, to more globally differentiate

137 ent gp120 elicited high levels of T cell and humoral immune responses, with the vector containing a d

138 on lymphocyte activation limits cellular and humoral immune responses.

139 ial for induction of potent and long-lasting humoral immune responses.

140 ccines continue to fail to induce these rare humoral immune responses.

141 ted roles of LCs in type 17, regulatory, and humoral immune responses.

142 an immune system to induce both cellular and humoral immune responses.

143 c portion of IgG and important regulators of humoral immune responses.

144 arding the optimal approach for induction of humoral immune responses.

145 IGHV polymorphism provides a rich source of humoral immune system diversity.

146 s are the effector molecules of the adaptive humoral immune system.

147 er, little is known about involvement of the humoral immune system.

148 mary immunodeficiency diseases affecting the humoral immune system.

149 one, as assessed by the primary endpoints of humoral immunity (neutralising antibodies-ie, seroconver

150 ugh prophylactic vaccines provide protective humoral immunity against infectious agents, vaccines tha

151 ses for long-lived cellular and neutralizing humoral immunity against the viral hemagglutinin.

152 However, the role of A2aR in humoral immunity and B cell differentiation is unknown.

153 The duration and quality of humoral immunity and generation of immunological memory

154 ght impair the TFH cell-dependent control of humoral immunity and might lead to the development of ab

155 B cells promoted restoration of cellular and humoral immunity and protection against opportunistic in

156 s that may be targeted to promote long-lived humoral immunity and resistance to malaria.

157 y target cells of rapamycin for the impaired humoral immunity and that reduced Tfh formation in rapam

158 Germinal centres (GCs) promote humoral immunity and vaccine efficacy.

159 haematopoiesis, although their functions in humoral immunity are difficult to decipher as a result o

160 However, whether and how mTOR regulates humoral immunity are not well understood.

161 s underlying the maintenance of long-lasting humoral immunity are not well understood.

162 Long-lived plasma cells are critical to humoral immunity as a lifelong source of protective anti

163 ed with defective CTL functions and impaired humoral immunity as indicated by reduced germinal center

164 ontribute to the development of long-lasting humoral immunity by germinal center formation.

165 We found that CXCL13 expression promoted humoral immunity by recruiting Tfh and GC B cells, facil

166 entify a mechanism by which IL-21 reinforces humoral immunity by restricting Tfr cell proliferation.

167 IL-10 also indirectly supports humoral immunity by suppressing excessive IFN-gamma, whi

168 Humoral immunity consists of pre-existing antibodies exp

169 s are essential for generation of protective humoral immunity during influenza infection.

170 1 regulatory (Tr1) cells, and restriction of humoral immunity during malaria blood stage infection.

171 hylaxis (PEP) requires rapid vaccine-induced humoral immunity for protection.

172 moniae infections, and underscore the effect humoral immunity has on evolving drug resistance.

173 bda light chain, thus potentially minimizing humoral immunity impairment.

174 ith correlation of CMV-specific cellular and humoral immunity in all subjects.

175 ry of contradictory evidence for the role of humoral immunity in defense against tuberculosis.

176 n ER-negative disease, suggesting a role for humoral immunity in mediating response to cytotoxic ther

177 nical course of disease suggesting a role of humoral immunity in S. aureus clearance.

178 ile malaria but did not increase with age as humoral immunity is acquired or correlate with protectio

179 Humoral immunity is an essential correlate of protection

180 from malaria in animal models but protective humoral immunity is difficult to induce in humans.

181 Humoral immunity is generated and maintained by antigen-

182 indicate that the escape of HIV-1 from host humoral immunity may play a direct role in TF in long-te

183 dentify mechanisms underlying persistent IgE humoral immunity over almost the entire lifespan of the

184 own whether these changes continue to affect humoral immunity postpartum or how quickly they resolve.

185 Plasma cells (PCs) as effectors of humoral immunity produce Igs to match pathogenic insult.

186 ion, a discriminatory or protective role for humoral immunity remains unclear.

187 Humoral immunity requires B cells to respond to multiple

188 lts establish PTIP as a licensing factor for humoral immunity that acts at several junctures of B lin

189 most critically, to identify the features of humoral immunity that distinguish protective from non-pr

190 allele was also associated with up-regulated humoral immunity through increased levels of soluble BAF

191 Tfh cell generation and prevented protective humoral immunity to intestinal helminth infection.

192 SS provides the potential to elicit humoral immunity to target Plasmodium at multiple stages

193 s to examine the contribution of B cells and humoral immunity to the control of TB in nonhuman primat

194 ile progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little

195 e in vivo, B cell responses to model Ags and humoral immunity upon influenza infection were enhanced.

196 Humoral immunity was associated with viral load at prese

197 Humoral immunity was identified as the correlate of prot

198 We found that impairment of humoral immunity was most outspoken in the first year af

199 Loss of either protein results in defective humoral immunity, and overexpression of ICOS results in

200 The elderly have reduced humoral immunity, as manifested by increased susceptibil

201 ot affect the development of anti-Bordetella humoral immunity, did not contribute to disease severity

202 eature has been associated with avoidance of humoral immunity, i.e., B cell activation and antibody n

203 n the critical contribution of complement to humoral immunity, our observations provide new mechanist

204 al fatty acid status is a factor influencing humoral immunity, potentially through an SPM-mediated me

205 ole of GS protein-coupled A2aR in regulating humoral immunity, which may be pharmacologically targete

206 rofound impact on CD4(+) T cell function and humoral immunity, yet the impact of aging on antigen spe

207 that IL-10 is essential for anti-Plasmodium humoral immunity.

208 ultiple Ags and generate robust cellular and humoral immunity.

209 elper T (Tfh) cells, which are essential for humoral immunity.

210 served peptide sequences from recognition by humoral immunity.

211 activation and the development of long-lived humoral immunity.

212 of soluble BAFF, which in turn up-regulated humoral immunity.

213 ibody/effector cell interaction in mediating humoral immunity.

214 then tested as adults for cell-mediated and humoral immunity.

215 barrier to their participation in protective humoral immunity.

216 of immune cell subsets involved in antiviral humoral immunity.

217 s and is a key component of HIV evasion from humoral immunity.

218 Cs in humans that contribute to long-lasting humoral immunity.

219 ered in pathophysiological states, modulates humoral immunity.

220 on and sustained expansion of GC B cells for humoral immunity.

221 y, especially for protection against EBV and humoral immunity.

222 r understanding disease mechanisms involving humoral immunity.

223 endosomal toll-like receptors and antiviral humoral immunity.

224 ress GC B cell responses and anti-Plasmodium humoral immunity.

225 mechanisms collaborate to provide protective humoral immunity.

226 s provide new insight into the regulation of humoral immunity.

227 mulatory receptor that enhances cellular and humoral immunity.

228 f strategies that elicit effective antiviral humoral immunity.

229 add to the understanding of anti-ebolavirus humoral immunity.IMPORTANCE This study describes the gen

230 mmunized with GP-alone, GP-alpha-syn (active humoral immunization), GP+RAP, or GP+RAP/alpha-syn (comb

231 SC transplantation including neutropenia and humoral immunodeficiency.

232 deletion displayed exacerbated leukocyte and humoral infiltration, neuropathology, motor disability,

233 e data suggest that modulation of the innate/humoral inflammatory microenvironment may impact the pot

234 ENDAT expression predicative of acute humoral injury is not reduced with complement inhibition

235 id-phase pattern recognition receptor of the humoral innate immune system with ancestral antibody-lik

236 Based on these findings, we hypothesize that humoral innate immunity may recognize senescent cells by

237 e CD28 blockade controlled both cellular and humoral memory recall in nonhuman primates and induced l

238 ted influenza viruses, which elicited robust humoral, mucosal, and cellular immunity against diverse

239 mal immunization whether it was evaluated by humoral or cellular immunity.

240 ical vaccine development will augment either humoral or cellular immunity.

241 combined vaccine is more effective than the humoral or cellular immunization alone.

242 rmining the effector populations involved in humoral protection against genital chlamydia infection i

243 hese findings establish a novel mechanism of humoral protection in the eye involving FcRn and may fac

244 bOPV provided humoral protection similar to tOPV against polio serotyp

245 .06-1.16; P < 0.001), severe vascular and/or humoral rejection (adjusted odds ratio, 1.06; 95% CI, 1.

246 Humoral rejection is the most common cause of solid orga

247 estration of DSAs protects islet grafts from humoral rejection.

248 et graft attrition, suggesting resistance to humoral rejection.

249 ne mechanisms involved (cell-mediated versus humoral) remain incompletely known.

250 een host and microbe, we analysed the memory humoral response against IsdB, a protein involved in iro

251 he aged host are associated with an impaired humoral response and a greater susceptibility to vancomy

252 e mechanisms by which this vaccine induces a humoral response and the role of T-cells in rVSV-EBOV me

253 The endogenous T cell-dependent humoral response can be protective.

254 ponses, capturing the array of functions and humoral response characteristics that may be induced fol

255 er, none of these reports have evaluated the humoral response during ZIKV infection.

256 pletion of CD4(+) cells after an established humoral response in immunized mice does not impair prote

257 We confirm the paucity of humoral response in patients with CM-FPIES.

258 also show a significant association with the humoral response in patients with digestive pathologies.

259 and play critical roles in the cellular and humoral response in solid organ transplantation.

260 This intracellular humoral response relies on opsonized viral particles rea

261 ion with the 4CMenB vaccine elicits a robust humoral response that correlates with protection against

262 act as an adjuvant in such a manner that the humoral response to a recombinant protein may be enhance

263 Vancomycin treatment decreases the systemic humoral response to CDI.

264 The humoral response to human immunodeficiency virus (HIV) r

265 nal lineages is crucial to understanding the humoral response to infection and immunization.

266 However, the humoral response to the PfCSP C terminus (C-PfCSP) is le

267 f DNA vectors may be limited by the impaired humoral response.

268 n injected alone, only adalimumab elicited a humoral response.

269 234 GEO, n = 384 TCGA) confirmed heightened humoral responses (CD20, CD22, AID) in melanoma.

270 th DFTD cancer cells can successfully induce humoral responses against DFTD and trigger immune-mediat

271 y of chimeric RHDV VLPs to elicit protective humoral responses against foreign antigens, we tested tw

272 ionally assess the neutralizing potential of humoral responses against malaria vaccine candidate anti

273 apacity of the NYVAC vector to trigger broad humoral responses and a more balanced activation of CD4(

274 facilitate assessment of functionally unique humoral responses and contribute to identification of co

275 roaches allowed us to highlight the focus of humoral responses and hypothesise new modes of pathogen

276 Monoclonal antibodies and vaccines targeting humoral responses are under development for prophylactic

277 there were no differences in malaria-induced humoral responses between WT and Cd36(-/-) mice.

278 compared to soluble OVA resulted in similar humoral responses but in a higher efficacy as assessed b

279 Evaluation of the humoral responses elicited by these novel immunogen desi

280 proliferation of CD4(+) T cells and optimal humoral responses following alum-adjuvanted immunization

281 ying immunological memory, which can broaden humoral responses following rabies vaccination.

282 Importantly, these humoral responses generate long-lived plasma cells and g

283 ations, hCD22 transgenic mice develop normal humoral responses in a peanut allergy oral sensitization

284 By contrast, the role of humoral responses in cutaneous immunity is underapprecia

285 ta as a means to better predict and optimize humoral responses in genetically diverse human populatio

286 Beginning in 2009, studies of the humoral responses of HIV-positive individuals have led t

287 Productive humoral responses require that naive B cells and their d

288 Generation of Ag-specific humoral responses requires the orchestrated development

289 define unique insights for understanding how humoral responses target virions and for developing rela

290 s after initial vaccination generated higher humoral responses than after RV144, but these responses

291 Defining the fine specificity of maternal humoral responses that partially protect against MTCT of

292 ammatory cytokines in the kidneys and normal humoral responses to immunization.

293 the magnitude and capacity of Pfs25-specific humoral responses to remain above a protective level.

294 epeated injections or osmotic pumps enhanced humoral responses, with exponentially increasing (exp-in

295 rvivin-deficient B cells are unable to mount humoral responses.

296 replication-deficient adenoviruses to induce humoral responses.

297 ibodies; mice and ferrets exhibited narrower humoral responses.

298 lls play opposing roles in the regulation of humoral responses: T follicular helper (Tfh) cells suppo

299 e generation, which suppresses antiviral and humoral signaling networks via modification of a unique,

300 ly activate STATs and could therefore act as humoral transfer factors of RIPC s cardioprotection.